$1.16 Million in Sales Expected for AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) This Quarter

Share on StockTwits

Equities analysts predict that AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) will post sales of $1.16 million for the current quarter, according to Zacks. Four analysts have made estimates for AcelRx Pharmaceuticals’ earnings, with the highest sales estimate coming in at $1.60 million and the lowest estimate coming in at $980,000.00. AcelRx Pharmaceuticals posted sales of $380,000.00 in the same quarter last year, which suggests a positive year over year growth rate of 205.3%. The firm is expected to issue its next earnings report on Friday, November 1st.

On average, analysts expect that AcelRx Pharmaceuticals will report full year sales of $4.90 million for the current financial year, with estimates ranging from $3.70 million to $5.80 million. For the next year, analysts anticipate that the firm will post sales of $29.21 million, with estimates ranging from $22.00 million to $38.60 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow AcelRx Pharmaceuticals.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last posted its quarterly earnings data on Monday, August 5th. The specialty pharmaceutical company reported ($0.16) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.07. The firm had revenue of $0.94 million during the quarter, compared to analysts’ expectations of $1.55 million.

Several equities research analysts have recently issued reports on ACRX shares. Credit Suisse Group started coverage on shares of AcelRx Pharmaceuticals in a research note on Monday, August 5th. They set an “outperform” rating and a $7.00 price target for the company. Zacks Investment Research lowered shares of AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 9th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $7.39.

In related news, Director Mark G. Edwards purchased 15,000 shares of the firm’s stock in a transaction dated Monday, August 26th. The stock was bought at an average price of $2.19 per share, for a total transaction of $32,850.00. Following the purchase, the director now directly owns 213,750 shares in the company, valued at approximately $468,112.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 7.50% of the company’s stock.

Several hedge funds have recently modified their holdings of ACRX. BlackRock Inc. grew its stake in AcelRx Pharmaceuticals by 149.8% in the 2nd quarter. BlackRock Inc. now owns 6,047,743 shares of the specialty pharmaceutical company’s stock valued at $15,301,000 after buying an additional 3,626,486 shares in the last quarter. D. E. Shaw & Co. Inc. grew its stake in AcelRx Pharmaceuticals by 199.8% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 859,971 shares of the specialty pharmaceutical company’s stock valued at $2,175,000 after buying an additional 573,139 shares in the last quarter. Vanguard Group Inc. grew its stake in AcelRx Pharmaceuticals by 15.5% in the 2nd quarter. Vanguard Group Inc. now owns 3,376,567 shares of the specialty pharmaceutical company’s stock valued at $8,542,000 after buying an additional 451,962 shares in the last quarter. Bank of New York Mellon Corp grew its stake in AcelRx Pharmaceuticals by 306.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 253,974 shares of the specialty pharmaceutical company’s stock valued at $643,000 after buying an additional 191,432 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in AcelRx Pharmaceuticals by 573.3% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 191,483 shares of the specialty pharmaceutical company’s stock valued at $485,000 after buying an additional 163,045 shares in the last quarter. Institutional investors own 21.40% of the company’s stock.

NASDAQ:ACRX remained flat at $$2.21 on Friday. 313,488 shares of the company’s stock traded hands, compared to its average volume of 647,282. The firm has a market cap of $175.55 million, a PE ratio of -2.73 and a beta of 2.11. AcelRx Pharmaceuticals has a 52-week low of $1.99 and a 52-week high of $5.05. The firm’s 50-day simple moving average is $2.32 and its two-hundred day simple moving average is $2.67.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

Recommended Story: What is the return on assets formula?

Get a free copy of the Zacks research report on AcelRx Pharmaceuticals (ACRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Dillard’s, Inc.  Shares Sold by Rhumbline Advisers
Dillard’s, Inc. Shares Sold by Rhumbline Advisers
Morgan Stanley Boosts Holdings in Safeguard Scientifics, Inc
Morgan Stanley Boosts Holdings in Safeguard Scientifics, Inc
Arcadia Biosciences Inc  Shares Acquired by Morgan Stanley
Arcadia Biosciences Inc Shares Acquired by Morgan Stanley
MidWestOne Financial Group, Inc.  Shares Bought by Morgan Stanley
MidWestOne Financial Group, Inc. Shares Bought by Morgan Stanley
Morgan Stanley Sells 2,891 Shares of NACCO Industries, Inc.
Morgan Stanley Sells 2,891 Shares of NACCO Industries, Inc.
Morgan Stanley Reduces Stock Position in United States Cellular Corp
Morgan Stanley Reduces Stock Position in United States Cellular Corp


 
© 2006-2019 Zolmax.